Market Access News | pharmaphorum

News

MSD eyes March FDA decision on PAH drug sotatercept

MSD has been granted a priority review by the FDA for its pulmonary arterial hypertension (PAH) candidate sotatercept, setting up a decision on the would-be blockbuster by

News

FDA advisors unconvinced by BrainStorm’s ALS cell therapy

An FDA advisory committee has voted by a huge margin that BrainStorm’s stem cell therapy for amyotrophic lateral sclerosis (ALS) – NurOwn – does not have enough data to su

News

NICE turns down Enhertu in “devastating” move, says charity

AstraZeneca and Daiichi Sankyo’s Enhertu should not be made available via the NHS for HER2-low metastatic or unresectable breast cancer after chemotherapy, according to pr

News

AscellaHealth recognised for rare disease funding programme

AscellaHealth has been given an industry award for a financial solution designed to meet the affordability challenges of expensive treatments for rare and complex diseases

News

CDC backs maternal use of Pfizer’s RSV vaccine

The way has been largely cleared for the rollout of Pfizer’s respiratory syncytial virus (RSV) vaccine to help protect newborns and infants from the virus after an advisor

News

Leqembi approved in Japan, its first ex-US market

Eisai and Biogen now have their second regulatory approval for anti-amyloid therapy Leqembi – in Japan – as a treatment for slowing the progression of Alzheimer’s disease.

MSD eyes March FDA decision on PAH drug sotatercept

FDA advisors unconvinced by BrainStorm’s ALS cell therapy

NICE turns down Enhertu in “devastating” move, says charity

AscellaHealth recognised for rare disease funding programme

CDC backs maternal use of Pfizer’s RSV vaccine

Leqembi approved in Japan, its first ex-US market

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks